Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
Molecular Case Studies · 2021-02 · 7 (1) · a005801
DOI: 10.1101/mcs.a005801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Case Studies, online erschienen am 19.02.2021. Verfasst von Deep Pandya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rudy L. Ruggles Biomedical Research Institute, Nuvance Health, Danbury, Connecticut 06810, USA. Hauptthemen laut MEDLINE: Germ Cells, Mutation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its incidence is expected to increase as castration-resistant disease emerges from the widespread use of potent androgen receptor-targeting therapies, such as abiraterone and enzalutamide. Defects in homologous recombination repair genes, such as BRCA1/2 , are also being increasingly detected in individuals with advanced prostate cancer. We present the case of a 65-yr-old man with a germline BRCA2 mutation who developed explosive treatment-emergent, small-cell neuroendocrine prostate cancer. He achieved a complete response to platinum-containing chemotherapy, but a limited remission duration with the use of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, as maintenance therapy. Upon relapse, tumor genomic profiling revealed a novel 228-bp deletion in exon 11 of the BRCA2 gene. The addition of the anti-PD1 drug pembrolizumab to olaparib was ineffective. This case highlights the ongoing challenges in treating neuroendocrine prostate cancer, even in the setting of homologous recombination repair deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rudy L. Ruggles Biomedical Research Institute, Nuvance Health, Danbury, Connecticut 06810, USA.
- Department of Medicine, Norwalk Hospital, Nuvance Health, Norwalk, Connecticut 06856, USA.
- Department of Pathology, Norwalk Hospital, Nuvance Health, Norwalk, Connecticut 06856, USA.
- Department of Radiology, Norwalk Hospital, Nuvance Health, Norwalk, Connecticut 06856, USA.
- Department of Urology, Norwalk Hospital, Nuvance Health, Norwalk, Connecticut 06856, USA.
Zitieren
APA
Pandya, D., Shah, M., Kaplan, F., Martino, C., Levy, G., Kazanjian, M., Batter, S., Martignetti, J., & Frank, R. C. (2021). Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. Molecular Case Studies, 7(1), a005801. https://doi.org/10.1101/mcs.a005801
Vancouver
Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, et al. Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. Molecular Case Studies. 2021;7(1):a005801. doi:10.1101/mcs.a005801
BibTeX
@article{Pandya2021,
author = {Pandya, Deep and Shah, Myra and Kaplan, Fuat and Martino, Candice and Levy, Gillian and Kazanjian, Mia and Batter, Stephen and Martignetti, John and Frank, Richard C},
title = {Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance},
journal = {Molecular Case Studies},
year = {2021},
volume = {7},
number = {1},
pages = {a005801},
doi = {10.1101/mcs.a005801}
}
EUVIMED